Thryv Therapeutics

Thryv Therapeutics

Edit info

  • Founded: 2019
  • Location: Montreal, QC
  • Employee range: 1-50
  • Clinical stage: Clin2
  • Therapy area: Drug induced long QT syndrome
  • Drug types: CVV, GEN, ONC
  • Lead product: Islatertib
  • Funding: 10-100M


thryvtrx.com

linkedin.com

job board


Drug notes:

Also Clin1 long QT syndrome type 1; THRYV-1257 Clin1 thyroid cancer, 3 efforts RD/Clin0 multiple cancers; LQT-1268 Clin0 atrial fibrillation, Clin0 heart failure

About:

Thryv Therapeutics is pioneering a precision medicine approach to treat genetic and drug-induced Long QT syndromes, atrial fibrillation and oncology. Central to Thryv’s approach is the use of SGK1 inhibitors - SGK1 is a protein kinase which regulates a number of ion currents in human cardiac cells and supports cell survival and proliferation in many resistant cancer cells. Thryv has rapidly advanced their portfolio of SGK1 inhibitors and have completed a Phase 1 healthy volunteer study for LQT-1213.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com